Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate the chance of non-healing diabetic foot ulcers repair by improving the condition of lack of oxygen or hypoxia in the wound area caused by diabetes using methylene blue along with the use of platelet-rich plasma-fibrin glue as an effective treatment for wound healing.
The current study assesses the effects of methylene blue along with the use of platelet-rich plasma-fibrin glue on wound healing in patients with nonhealing diabetic foot ulcers (non-healing DFU). This randomized controlled trial is performed on 20 patients with non-healing DFU. Patients were treated with PRP-FG dressing plus 200 ml of oral methylene blue dissolved in milk(intervention group) or PRP-FG dressing plus placebo (200 ml of milk) (control group) for 4 weeks.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Methylene Blue | Experimental | The first intervention group (group A) includes diabetic patients with chronic foot ulcers who, despite common treatments, will be undergone oral methylene blue intervention (70 mg in 200 ml of milk) for 4 weeks. |
|
| Milk (control) | Experimental | Patients with non-healing Diabetic Foot Ulcers only will receive 200 ml of milk for 4 weeks. |
|
| Methylene Blue and Platelet-Rich Plasma-Fibrin Glue | Experimental | Patients with non-healing Diabetic Foot Ulcers will treat with PRP-Fibrin-Glue plus oral methylene blue (70 mg in 200 ml of milk) for 4 weeks. |
|
| Milk and Platelet-Rich Plasma-Fibrin Glue (control) | Experimental | Patients with non-healing Diabetic Foot Ulcers will be treated with PRP-Fibrin-Glue and 200 ml of milk for 4 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Methylene Blue | Drug | The first intervention group includes diabetic patients with chronic foot ulcers who, despite common treatments, will be undergone oral methylene blue intervention for 4 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| The healing rate of the ulcer | Measurement of wound area with a ruler | 4 weeks |
| Wound Size | Wound size will be measured with a ruler for length, and width as well as with digital imaging. Wound size will be assessed in digital images taken of the wound. | 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| TcPO2 at baseline and after the intervention | Transcutaneous oxygen tension (TcpO2) provides information about blood perfusion in the tissue immediately below the skin. (blood pressure, measured in millimeters of mercury (mmHg)) | 4 weeks |
| Oxygen saturation at baseline and after the intervention |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Daryoush Hamidi Alamdari, Ph.D | Contact | +98 51 3882 8574 | hamidiad@mums.ac.ir | |
| Elaheh Emadi, Ph.D | Contact | +98 9355850931 | EmadiE4001@mums.ac.ir |
| Name | Affiliation | Role |
|---|---|---|
| Daryoush Hamidi Alamdari, Ph.D | Mashhad University of Medical Sciences, Mashhad, Iran | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mashhad University of Medical Sciences | Recruiting | Mashhad | Razavi Khorasan Province | 99191-91778 | Iran |
All data related to the project after the unidentifiable people will be shared.
Access to data is allowed 6 months after the publication of results.
The investigator's data will be available to university staff and academic institutions.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Milk (control) | Other | Group B will receive 200 ml of milk for 4 weeks. |
|
|
| Methylene Blue and Platelet-Rich Plasma-Fibrin Glue | Drug | Group C will be undergone synergistic 4-week treatment with oral methylene blue and fibrin glue. |
|
|
| Milk and Platelet-Rich Plasma-Fibrin Glue (control) | Other | Group D will be treated only with fibrin glue and 200 ml of milk for 4 weeks. |
|
|
Blood must contain a normal concentration of hemoglobin. that hemoglobin must be >95 % saturated with oxygen in arterial blood (sO2(a) >95 %) |
| 4 weeks |
| Blood pressure (systolic and diastolic) | The pressure of the blood in the circulatory system | 4 weeks |
| The resting systolic toe pressure (TP) at baseline and after the intervention | The toe cuff with the sphygmomanometer is slowly inflated until the waveform flattens (generally between 150-200 mmHg), then is inflated a further 20 mmHg. The cuff is slowly released at a rate of 2-5mmHg per second. The first regular cyclical waveform is considered the toe systolic pressure. | 4 weeks |
| Serum IL-1β levels at baseline and after the intervention | Analysis of serum interleukin-1β levels | 4 weeks |
| Serum MCP-1 levels at baseline and after the intervention | Analysis of serum monocyte chemoattractant protein-1 (MCP-1) levels | 4 weeks |
| Serum TNF-α levels at baseline and after the intervention | Analysis of serum tumor necrosis factor α (TNFα) levels | 4 weeks |
| Serum IL-6 levels at baseline and after the intervention | Analysis of serum interleukin-6 (IL-6) levels | 4 weeks |
| Serum HIF-1α levels at baseline and after the intervention | Analysis of serum hypoxia-inducible factor 1-alpha (HIF-1α) levels | 4 weeks |
| Serum FBS levels at baseline and after the intervention | Analysis of serum fasting blood sugar (FBS ) levels | 4 weeks |
| Serum Insulin levels at baseline and after the intervention | Analysis of Insulin levels | 4 weeks |
| Lipid Profile at baseline and after the intervention | Serum Triglyceride, Cholesterol, HDL, LDL, VLDL | 4 weeks |
| Serum Urea at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum Creatinine at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum total bilirubin at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum Vitamin D levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| HbA1c at baseline and after the intervention | Glycated hemoglobin | 4 weeks |
| Serum Albumin (Alb) levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Uric Acid levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum Homocysteine levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum ALT (alanine transaminase) levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum AST (Aspartate Transferase) levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum ALP (alkaline phosphatase) levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum Met Hemoglobin levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum Hemoglobin (Hgb, Hb) levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum white blood cells (WBCs) levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum total Lymphocyte levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Platelet count at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Nitric oxide blood at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum lactate dehydrogenase (LDH) levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum Erythrocyte Sedimentation Rate (ESR) levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Serum C-Reactive Protein (CRP) levels at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| Neutrophils count at baseline and after the intervention | In a quantitative laboratory method | 4 weeks |
| ID | Term |
|---|---|
| D017719 | Diabetic Foot |
| ID | Term |
|---|---|
| D003925 | Diabetic Angiopathies |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D016523 | Foot Ulcer |
| D007871 | Leg Ulcer |
| D012883 | Skin Ulcer |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |
| D003929 | Diabetic Neuropathies |
Not provided
Not provided
| ID | Term |
|---|---|
| D008751 | Methylene Blue |
| D008892 | Milk |
| ID | Term |
|---|---|
| D010640 | Phenothiazines |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D001628 | Beverages |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D003611 | Dairy Products |
| D005502 | Food |
| D019602 | Food and Beverages |
Not provided
Not provided